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The glycosaminoglycan (GAG) hyaluronic acid (HA) is a protein-free polymer of disaccharide units containing glucuronic
acid and N-acetylglucosamine (1, 2). HA is involved in many
physiological processes (3), such as wound healing, development, and metastasis of some cancers (4–8). The typical molecular mass of the polysaccharide ranges from just a few thousand Da (tens of sugars) that are thought to be important in
cellular signaling (6) to several million Da (tens of thousands
of sugars). These larger forms of HA are present throughout
the body and are particularly concentrated within the bursa
of major joints, such as the knee, where they help to provide
shock absorbance in cartilage or lubrication in synovial fluid
(9, 10), and the eye, where HA maintains structural integrity of the vitreous humor (11). The adult human body contains ~15g of HA, of which about 5 g are turned over daily
(12). Partially degraded HA perfuses from extracellular matrices (ECMs) and enters the lymphatic and vascular circulation
systems, where it is catabolized to shorter fragments. This active maintenance of HA turnover must be efficient in order to
maintain homeostatic conditions for total body HA.
All of the other GAGs, including the chondroitin sulfates
(CSs), heparan sulfate (HS), and keratan sulfate, are linked
to core proteins (as proteoglycans) that help to form ECMs,
such as the basement membranes of tissues, or structural
components of organs, such as the vitreous humor. There are
over 30 known core proteins that are essential for a diverse
array of functions, such as neural development, growth factor signaling, and pathogen recognition (13). These core proteins are found as prevalent components of tissue ECMs or
as specialized components needed for the development of
microenvironments that interface a specialized tissue cell
type with the ECM. Both the proteoglycans and their attached GAG chains may combinatorially interact with ligands and contribute to modulation of the functional aspects of a particular microenvironment (e.g. CS interacting
with apolipoprotein E for uptake of β-very low density lipoprotein in hippocampal neurons) (14). Although numerous
studies have focused on how the inhibition of some CS proteoglycans enhances neural development, especially in injured spinal cord models, there is very little information on
how CS and HS are catabolized. The current model is that
extracellular chondroitinases, heparinases, and proteases ini-

Abstract
The hyaluronic acid (HA) receptor for endocytosis (HARE;
also designated stabilin-2 and FEEL-2) mediates systemic
clearance of glycosaminoglycans from the circulatory and
lymphatic systems via coated pit-mediated uptake. HARE is
primarily found as two isoforms (315- and 190-kDa) in sinusoidal endothelial cells of the liver, lymph node, and spleen. Here
we characterize the ligand specificity and function of the large
stably expressed 315-HARE isoform in Flp-In 293 cell lines.
Like human spleen sinusoidal endothelial cells, Flp-In 293 cell
lines transfected with a single cDNA encoding the full-length
315-HARE express both the 315-kDa and the proteolytically
truncated 190-kDa isoforms in a ratio of ~3–4:1. The 190kDa HARE isoform generated from the 315-kDa HARE and
the 315-kDa HARE specifically bound 125I-HA. Like the 190kDa HARE expressed alone (Harris, E. N., Weigel, J. A., and
Weigel, P. H. (2004) J. Biol. Chem. 279, 36201–36209), the
190- and 315-kDa HARE isoforms expressed in 315-HARE
cell lines were recognized by anti-HARE monoclonal antibodies 30, 154, and 159. All 315-HARE cell lines could endocytose and degrade 125I-HA. Competition studies with live cells
indicate that 190-HARE and 315-HARE bind HA with higher
apparent affinity (Kd ~10–20 nm) than chondroitin sulfate (CS)
types A, C, D, or E. Only slight competition of HA endocytosis was observed with CS-B (dermatan sulfate) and chondroitin. Direct binding assays with the 315-HARE ectodomain revealed high affinity HA binding, and lower binding affinities for
CS-C, CS-D, and CS-E. A majority of each HARE isoform was
intracellular, within the endocytic system, suggesting transient surface residency typical of an active endocytic recycling
receptor.
Abbreviations: GAG, glycosaminoglycan; BSA, bovine serum albumin; CS, chondroitin sulfate; CS-A, chondroitin 4-sulfate; CS-C, chondroitin 6-sulfate; CS-D, chondroitin 2,6-sulfate; CS-E, chondroitin
4,6-sulfate; ECM, extracellular matrix; HA, hyaluronic acid, hyaluronate, hyaluronan; HARE, HA receptor for endocytosis; hHARE, human HARE; HBSS, Hanks’ balanced salts solution; HS, heparan sulfate; mAb, monoclonal antibody; PBS, phosphate-buffered saline;
s190-HARE, soluble 190-kDa HARE ectodomain; s315-HARE, soluble ectodomain of the 315-kDa HARE; 190-HARE, the 190-kDa HA
receptor for endocytosis; 315-HARE, the 315-kDa HA receptor for
endocytosis; s190- and s315-HARE, soluble 190- and 315-HARE, respectively; ELISA, enzyme-linked immunosorbent assay; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum
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tially break down these GAGs and proteoglycans, and their
final digestion can then take place intracellularly at the local
tissue level. However, in many cases, some of these GAGs
and proteoglycan fragments will probably find their way
into the lymphatic and circulatory systems, especially during injury or disease. Without some type of efficient GAGclearing mechanism, these fluid circulatory systems may get
overwhelmed with large amounts of debris derived from tissue ECMs throughout the body.
Although the synthesis and catabolism of HA are generally
the most understood pathways of any of the GAGs, the details of each pathway currently remain largely unknown. In
the early 1980s, it was observed that liver sinusoidal endothelial cells endocytose circulating HA (15–19). We know now
that HA·HARE complexes are endocytosed via the clathrincoated pit pathway (20, 21), and their formation is cation-independent (22), specific, and of high affinity (23, 24). Like the
mannose, low density lipoprotein, and asialoglycoprotein receptors, HARE is a recycling receptor that moves through
an intracellular itinerary every ~10–15 min (25). This receptor system was shown to be responsible for the physiological
turnover of about one-third of the total body HA per day (12,
26). Most of the partially degraded HA perfusing from a tissue ECM encounters this HA receptor first in lymph nodes,
which catabolize about 85% of the HA turning over daily. The
remaining 15% of the HA drains from the lymphatics into the
circulatory system and is removed by the same receptors present in liver sinusoidal endothelium. This rapidly recycling HA
receptor is also present in high copy number in spleen, where
it presumably mediates additional, but unknown, HA/GAG
activities other than systemic clearance.
The primary scavenger receptor for systemic HA turnover is HARE. Orthologues of this receptor are present in
other mammals, including cow, pig, guinea pig, rat, mouse,
and human (27). Human and rat HARE are primarily found
in the sinusoidal endothelial cells of the lymph nodes, liver,
and spleen (28–31). Additionally, mouse HARE/Stab-2 has
been detected in specialized tissues, such as the corneal and
lens epithelium, mesenchymal cells of heart valves, and prismatic epithelial cells covering the renal papillae (27), and bovine HARE has been reported in the oviduct (32).
The HARE proteins were first purified from rat liver (33)
and human spleen (30) and then molecularly cloned from rat
and human RNA pools (29–31). The hHARE is encoded by
a single gene found on chromosome 12q23.3 spanning 180.2
kb and containing 69 exons. The gene encodes a 2551-amino
acid glycoprotein with a molecular mass of ~315 kDa in SDSPAGE. A primary function of this receptor is to bind and internalize HA for turnover, although other GAGs, such as the
CSs (20, 34–37) (this report) are also internalized by this receptor, and advanced glycation end products appear to be
ligands as well (38, 39). The internalized receptor traffics
through the early endocytic pathway and is recycled to the
cell surface (21, 29, 37, 39). A 20-min recycling time was observed for the rat 175-kDa HARE expressed in SK-Hep1 cell
lines, whereas a 7–9-min cycle rate was observed with the
190-kDa hHARE expressed in Flp-In 293 cells. These inconsistent receptor recycling times may be dependent on intrinsic cell machinery differences.
Although our group has studied the biological activity
of rat and human HARE, we have focused primarily on the
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smaller 190-kDa HARE isoform. Other groups have focused
on the full-length HARE in human, mouse, pig, and cattle and
overlooked the smaller isoform as a breakdown product or an
experimental anomaly. Thus, confusion has arisen about this
particular receptor, including the existence of the smaller form
(175 kDa in rat, 190 kDa in human), where it comes from,
whether it is functional, and, if so, what the biological implications may be (40, 41). For example, the ratio of rat 175-HARE
to 300-HARE in the liver is higher than in the spleen. Thus, the
levels of each isoform appear highly regulated (30, 33), but it
is still not known why or how this occurs. We recently confirmed that the 190-kDa hHARE is, in fact, a functional endocytic recycling receptor that can mediate GAG uptake in the
absence of the larger 315-kDa hHARE (37).
In this report, we stably expressed the recombinant fulllength 315-kDa human HARE, using cDNA derived from
human lymph node, and show that a small fraction of the
total parent receptor is proteolytically cleaved to produce a
functional 190-kDa receptor. Thus, the 315-HARE expressed
in stable Flp-In 293 cell lines produces two receptors that
bind to and internalize HA. The secreted ectodomain of the
315-kDa receptor was glycosylated; was reactive with antiHARE monoclonal antibodies (mAbs); bound HA, CS-C,
CS-D, and CS-E well; and bound more weakly to CS-B and
chondroitin. When expressed in Flp-In 293 cells, most of the
receptors are found intracellularly, suggesting that as the receptor cycles between plasma membrane and endocytic vesicles, the time spent on the surface is quite short.

Experimental Procedures
Materials, Solutions, and Buffers—Tris-HCl, glycine, and
acrylamide were obtained from Research Products International (Mt. Prospect, IL); MgCl2, SDS, and methanol were
from EMD (Gibbstown, NJ); Triton X-100, o-nitrophenyl-βd-galactoside, digitonin, Tween 20, saponin, cetylpyridinium chloride, secondary antibodies conjugated to alkaline
phosphatase, heparin, ampicillin, and imidazole were obtained from Sigma. Formaldehyde without methanol for cell
fixation was from Polysciences, Inc. (Warrington, PA). All
GAGs except HA and heparin were from Seikagaku Corp.
(Tokyo, Japan) and characterized by size exclusion chromatography/multiangle laser light scattering. HA, prepared
from bacterial fermentation, was obtained from Genzyme
Corp. (Cambridge, MA). Flp-In 293 cells, serum, DMEM, hygromycin B, zeocin, glutamine, plasmid expression vectors,
supercompetent TOP10 Escherichia coli, and Lipofectamine
2000 were from Invitrogen. Anhydrous Me2SO and CuCl2
were obtained from Acros Chemical (Morris Plains, NJ). 125I
(100 mCi/ml; specific activity of >0.6 TBq/mg) in NaOH
and Sepharose 6 Fast Flow (nickel-nitrilotriacetic acid) resin
were from Amersham Biosciences. 125I-HA and 125I-streptavidin were prepared as described previously (42, 43). Streptavidin, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl,
biotin-LC-hydrazide, and sulfo-NHS-SS-biotin were purchased from Pierce. p-Nitrophenyl phosphate reagent was
from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg,
MD), and ELISA strips were from Nunc (Roskilde, Denmark). Affinity-purified polyclonal goat anti-V5 antibody
and goat anti-V5 antibody resin were obtained from Bethyl
Laboratories (Montgomery, TX). Affinity-purified anti-V5
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mAb was from Serotec (Oxford, UK). Anti-actin mAb (I-19)
and Protein A/G Plusagarose were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Taq polymerase for DNA end
modifications and screening was from Continental Laboratory Products (San Diego, CA), and pfu Ultra for cloning was
from Stratagene (La Jolla, CA). We purified DNA from agarose or aqueous solutions using Qbiogene Bio 101 DNA purification kits (Carlsbad, CA). We used either colorimetric
or chemiluminescence detection of blotted protein for Western blot analysis. Colorimetric reagents (p-nitro blue tetrazolium and sodium 5-bromo-4-chloro-3-indolyl phosphate
p-toluidine) and the chemiluminescence reagents (Luminol
and peroxide solutions) were from Pierce. Concentrator/desalting cartridges were from Amicon (Bedford, MA). TBST
contains 20 mm Tris-HCl, pH 7.0, 150 mm NaCl, and 0.1%
Tween 20. TBST/BSA is TBST with 1.0% (w/v) BSA. Coating Buffer for ELISA assays contains 15 mm Na2CO3, 36 mm
NaHCO3, pH 9.5. HBSS contains 5 mm KCl, 0.4 mm KH2PO4,
0.8 mm MgSO4, 137 mm NaCl, 0.3 mm Na2HPO4, 5.5 mm
glucose, 1.26 mm CaCl2, 0.5 mm MgCl2, and 28 μm phenol
red. At the time of use, 3.5 g/100 ml of NaHCO3 was added,
and the pH was adjusted to 7.0 with HCl. Z-buffer for the
β-galactosidase activity assay contains 60 mm Na2HPO4, 40
mm NaH2PO4, 10 mm KCl, 1.0 mm MgSO4, 50 mm 2-mercaptoethanol, pH 7.0.
Construction of the 315-HARE Expression Vector—Due to
the large size of the cDNA, the 315-kDa hHARE coding region was amplified from lymph node cDNA pools (Marathon System; BD Biosciences) using pfu Ultra in two sections
that overlapped by 484 nucleotides. The 5′-half of the cDNA
was amplified using gene-specific forward (5′-GGATCCATGATGCTACAACATTTAGTAATTTTTTGTCTTGG-3′)
and reverse (5′-GGTCATTATGGAGAAAGAAGCTCAGGAAATAGGAG-3′) primers, whereas the 3′-half of the
cDNA was amplified using gene-specific forward (5′-TCCTTACCAAACCTGCTCATGCGGCTGGAACAG-3′) and reverse (5′-GGATCCCAGTGTCCTCAAGGGGTCATTGCC-3′)
primers. Both cDNA sections were purified, mixed, denatured, and allowed to hybridize together, and the complementary strands were filled in using pfu Ultra. Using the forward primer for the 5′-half and the reverse primer for the
3′-half, we then amplified the entire 315-HARE encoding
cDNA (35 cycles, Tm = 55 °C, extension time = 8 min). Immediately following the amplification, 2.5 units of Taq polymerase and 2 mm MgCl2 were added to the reaction mixture,
which was incubated for 10 min at 72 °C to add free deoxyadenylate on the 3′-ends of the PCR product for compatible cloning in the TOPO line of expression vectors. The PCR
product representing the full-length 315-HARE cDNA was
purified by agarose gel electrophoresis using a 0.8% (w/v)
gel containing 0.002% crystal violet for band visualization.
The band was excised with a clean razor blade, gene-cleaned,
ligated into pcDNA5/FRT/V5/His6-TOPO, and transformed into TOP10 E. coli cells. Colonies growing on LB-ampicillin plates were screened for cDNA inserts by visualizing
total extracted nucleic acid on 1% agarose gels stained with
ethidium bromide. Colonies with potential HARE cDNA
were verified by PCR using gene-specific forward (5′-GTTCCATCTACGATCGCCACTGGGCCAG-3′) and vector-specific reverse (5′-CGTAGAATCGAGACCGAGGAG-3′) primers. The complete sequences of the promoter and complete
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coding regions of cDNAs in the final clones were determined
to be correct before they were used in subsequent experiments. This full-length HARE DNA sequence obtained was
identical to that of NCBI accession entry NM_017564 with
the exception of silent mutations located at codons 833, 1112,
1700, 1937, 2005, and 2175 and one missense mutation, which
created a D1276A mutation. However, Ala1276 was reported
in an earlier entry for stabilin-2 (accession number AJ295695)
and was also present in the 190 hHARE clones reported by
Harris et al. (37). The D1276A change does not appear to affect the biological activity of the receptor and probably represents a polymorphism in the human STAB2 gene. All protein expression experiments were performed using this
NM_017564-like cDNA.
Selection and Verification of 315-hHARE Cell Lines—Cell
lines were produced and characterized as described by Harris et al. (37) with minor modifications. Flp-In 293 cells (3 ×
106; Invitrogen) were plated in a 100-mm dish 2 days prior
to transfection. Cells incubating in 10 ml of fresh antibioticfree DMEM supplemented with 8% fetal bovine serum were
transfected by the addition of 750 μl of serum-free DMEM
containing 1.0 μg of pcDNA5/FRT/315-HARE V5/His6,
9.0 μg of pOG44 (encoding the Flp-In recombinase) and 20
μl of Lipofectamine 2000. Starting 24–36 h post-transfection,
the medium was replaced every 2–3 days with DMEM plus
8% FBS containing 100 μg/ml hygromycin B. Visible circular
colonies were present about 2 weeks post-transfection and
isolated using a P20 pipette with P200 tips. About 40 colonies were isolated by gently nudging with the tip while aspirating no more than 10 μl at a time. Medium on the plate
was changed after picking every five colonies to reduce the
chance of aspirating free-floating cells. Isolated colonies
were grown in 24-well dishes in DMEM plus 8% FBS with
100 μg/ml hygromycin B. After a monolayer of cells had developed from each clone, cells were scraped in 1 ml of medium and partitioned into four portions. One portion (100
μl) was reseeded in fresh medium and allowed to continue
growing in the 24-well dish. The second portion (100 μl) was
reseeded in 100 μg/ml zeocin to test for zeocin sensitivity.
The third portion (400 μl) was pelleted and resuspended in
50 μl of 4× Laemmli sample buffer (44) to test for HARE expression by SDS-PAGE followed by Western analysis using
anti-V5 antibody.
The remaining 400 μl of cell suspension was pelleted and
assayed for β-galactosidase activity. In addition to the zeocin sensitivity test, the β-galactosidase test indicates whether
the HARE-encoding plasmid integrated specifically and correctly into the genomic FRT site, which is the unique feature of the Flp-In cell line series. The cell pellet for this assay was resuspended in 200 μl of PBS containing 0.5% Triton
X-100 and 20 μl of cell lysate per well of a 96-well plate was
combined with 70 μl of Z-buffer and 20 μl of 4.0 mg/ml
o-nitrophenyl-β-d-galactoside in Z-buffer. After 15–30 min at
37 °C, the absorbance values were measured at 405–420 nm.
Lysates from HEK Flp-In 293 and HEK 293 cells were used
as positive and negative controls, respectively. Stable cell
lines were selected for further study only if they grew well in
DMEM containing 8% FBS and 100 μg/ml hygromycin B and
showed HARE expression, hygromycin B resistance, zeocin
sensitivity, no β-galactosidase activity, and normal cell morphology as determined by phase-contrast microscopy.
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Endocytosis and Degradation of 125I-HA—The C-terminal epitope tags do not interfere with HA binding, internalization, or trafficking mediated by the 190-kDa HARE (37).
Stably transfected cell lines expressing the 315-HARE were
plated in 12-well dishes and allowed to grow in DMEM with
8% fetal calf serum supplemented with 100 μg/ml hygromycin B at least 2 days prior to an experiment. Cells were
washed with HBSS and incubated for 60 min with fresh medium containing 0.075% BSA to allow HARE-mediated internalization of any serum GAGs that might be bound to the
cell surface. The same DMEM-BSA medium containing 1–2
μg/ml 125I-HA was then incubated with cells with or without the noted GAG as a competitor. Endocytosis or binding only of 125I-HA was measured by incubating cells at 37
or 4 °C, respectively. To determine HA binding by the total cell receptor population, cells on ice were permeabilized
with 0.055% (w/v) digitonin (using a 25% stock solution)
dissolved in anhydrous Me2SO (45). At the indicated times,
cells were washed three times with ice-cold HBSS and lysed
in 0.3 n NaOH, and radioactivity and protein content (46)
were determined.
Degradation of 125I-HA was measured by a cetylpyridinium chloride precipitation assay, as reported previously
(47). Briefly, 50 μl of sample medium was mixed with 0.25
ml of a 1.0 mg/ml solution of HA (as a carrier) in 1.5-ml microcentrifuge tubes. Alternatively, 100-μl samples of cell lysates in 0.3 n NaOH were mixed with 47 μl of 0.6 n HCl, 28
μl of distilled water, and 125 μl of 2.0 mg/ml carrier HA solution. After mixing at room temperature, 300 μl of 6% (w/v)
cetylpyridinium chloride in distilled water was added to
each tube and vortexed. The samples were allowed to precipitate for 10 min, followed by centrifugation at 8600 × g
for 5 min in an Eppendorf 5417 using a swinging bucket rotor. A 300-μl sample of the supernatant was taken for radioactivity determination, and the remaining supernatant was
removed by aspiration. The bottoms of the tubes containing the pellet were cut off and placed in 12 × 75-mm plastic
tubes for radioactivity determination using a Packard Cobra
II γ counter. Degradation was calculated as the time-dependent increase of nonprecipitable radioactivity. At least 80%
of the total radioactivity was precipitable at the beginning of
each experiment.
Western and Ligand Blot Assays—Cell lysates or immunoprecipitates were mixed with 4× Laemmli sample buffer (44)
without reducing agent and analyzed by SDS-PAGE using
a 5% gel. Protein electrotransfers to nitrocellulose were performed using a Bandit Electroblotter (Owl Scientific; Rochester, NY) for 1.5 h at 4 °C at 110 constant V in 25 mm Tris, 192
mm glycine, pH 8.3, and 15% methanol, pH 8.3. Subsequent
steps were at room temperature. For Western analysis (48),
the nitrocellulose membranes were treated with TBST/BSA
for at least 2 h to block nonspecific binding sites followed by
incubation in TBST/BSA with 1 μg/ml anti-rat HARE mAb
or 1:5000 anti-V5 antibody. After washing three times with
TBST, the blots were incubated with the appropriate secondary antibody conjugated with alkaline phosphatase or horseradish peroxidase, followed by three washes, and then detection with the appropriate reagents. When necessary, the
blots were stripped of bound antibodies by incubating the
membranes in 100 mm 2-mercaptoethanol, 2% SDS, 62.5 mm
Tris-HCl, pH 6.7, at 55 °C for 30 min. After several washes in
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TBST, the blots were reprobed with anti-V5 mAb. Densitometry was performed using an Fluor-Chem 8000 gel visualization and analysis system (Alpha Innotech Corp., San Leandro, CA).
For 125I-HA ligand blots (49), the nitrocellulose membrane
was incubated with TBST for at least 2 h at 4°C followed by
an incubation with 1 μg/ml 125I-HA in PBS containing 150
mm NaCl, 10 mm HEPES, pH 7.4, 5 mm EDTA, with or without 100 μg/ml unlabeled HA as competitor to assess nonspecific binding. Following a 2-h binding incubation at 4 °C, the
membrane was washed with excess TBST at least five times
over 30 min and dried at room temperature. Bound 125I-HA
was detected by autoradiography using Eastman Kodak Co.
MS film exposed at –80 °C for 24–48 h.
The method for biotin-GAG ligand blots was a modification of the above HA ligand blot procedure in which the
membrane with blotted proteins was incubated with a specific amount of biotin-GAG, washed, and detected with 125Istreptavidin. Biotin-GAGs were made according to the protocol of Yu and Toole (50), and a biotin quantification kit
(Vector Laboratories, Burlingame, CA) was used to determine the number of biotins/GAG chain. The molar mass and
concentration of each GAG were determined by size exclusion multiangle laser light scattering before and after the biotinylation reactions to ensure the addition of 1–2 biotins per
GAG chain, without GAG degradation, and to calculate the
final yield of each biotin-GAG.
Endoglycosidase F Treatment and Immunoprecipitation—
HARE was immunoprecipitated from cell lysates or media
containing 0.5% Nonidet P-40 and protease inhibitors (1 μg/
ml leupeptin, 1 μg/ml pepstatin A, 30 μg/ml phenylmethylsulfonyl fluoride) using anti-rat HARE mAbs 30, 154, and
159 attached to CNBr-activated Sepharose (0.3 mg/ml each
mAb) and allowed to rotate overnight at 4 °C. If the sample was to go straight to Western analysis, the resin was
washed twice with PBS and eluted with an equal volume of
4× Laemmli buffer and centrifuged briefly to pellet the resin.
If the sample was to be treated with endoglycosidase F, the
centrifuged resin was washed twice with PBS and incubated
with an equal volume of PBS containing 1% SDS to disrupt
antibody-HARE binding. The supernatant recovered after
centrifugation was adjusted to 1% Nonidet P-40 and incubated with 1.0 unit of N-glycosidase F (Roche Applied Science) overnight at 37 °C. The sample was then mixed with
0.25 volumes of 4× Laemmli buffer, separated by 5% SDSPAGE, and analyzed by Western blot assays.
Fluorescence Microscopy—Cells were grown on 18-mm
glass coverslips in complete medium for at least 2 days prior
to fixation. Cells were washed twice with PBS and fixed in
PBS containing 1% formaldehyde for 1 h at room temperature, followed by two rinses in PBS. Nonspecific antibody interactions were blocked with PBS containing 0.25% BSA for
30 min. Alternatively, cells were permeabilized (45) with
0.05% saponin for 30 min at room temperature after the
blocking procedure. Cells were incubated with both primary
and secondary antibodies in PBS containing 0.25% BSA for
1 h and washed between incubations. Glass coverslips were
mounted onto glass slides immediately prior to visualization
using a Nikon Diaphot 300 fluorescence microscope. Images
were captured with a DXM1200 side-mounted camera operated by Act-1 software version 2.6.3.
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Secreted Receptor Constructs—cDNA constructs for the secreted ectodomains of both the 315- and 190-HARE were
produced by deleting the transmembrane and cytoplasmic domains, while retaining the V5 and His6 tags. A single
primer, 5′-GTGACCTTGACCCACACTGGATCCGAAGGTAAGCCTATC-3′, was used in individual mutagenic reactions with the wild type HARE cDNAs (315-HARE in
pcDNA5/FRT/V5/His, 190-HARE in pSecTag/FRT/V5/
His) in an Ericomp thermocycler for 18 cycles (94 °C for 30
s, 63 °C for 30 s, 71 °C for 1 min/plasmid kb) using pfu Ultra. After the reaction, the plasmid was ethanol-precipitated
and resuspended in 17 μl of H2O, 2 μl of NEB4 buffer, and
2.5 units of DpnI to cut the template plasmid while retaining
the intact mutant plasmid. After an overnight incubation at
37 °C, the digest mix was heated to 95 °C for 10 min, cooled,
and immediately transformed into TOP10 supercompetent
E. coli cells. Bacterial cells containing the plasmid of choice
were screened by a miniprep procedure, and PCR and DNA
sequencing confirmed the mutation. Plasmids containing the
desired mutation were used to make stable cell lines, which
were created and evaluated as described above.
Soluble HARE Purification—s190-HARE or s315-HARE
was purified from pooled cell growth media (DMEM containing 8% FBS and 100 μg/ml hygromycin B) via the His6
tag. To remove particulate matter, conditioned medium (incubated with cells for at least 2 days) was centrifuged at 1500
rpm for 4 min. Clarified medium was supplemented with the
following to the indicated final concentrations: 10% glycerol,
250 mm NaCl, 10 mm imidazole. A 1% volume of 50% slurry
of Ni2+-charged Sepharose 6 Fast Flow resin (Amersham Biosciences) was added, and the mixture was incubated overnight at room temperature with gentle rotation. The resin
was captured in a 25-ml column, washed with 10 column
volumes of PBS containing 10 mm imidazole, and then
eluted with 4 column volumes of PBS containing 400 mm
imidazole. The partially purified HARE was concentrated
using a 30-kDa molecular mass cut-off concentrator and separated by SDS-PAGE on a 5% gel. The gel was stained with a
4% CuCl2 solution to visualize protein bands, and the HARE
band was cut out of the gel with a clean razor blade, minced,
and electroeluted overnight in dialysis tubing (35 V, 4 °C) in
185 mm glycine, 25 mm Tris-HCl, pH 8.5, 0.07% SDS. The final purified HARE preparation was concentrated to 0.1–1.0
mg/ml as above, washed twice with PBS, and stored at –20
°C until use in subsequent assays.
ELISAs—All steps were carried out at 37 °C. A set amount
of HARE protein in Coating Buffer (200 μl) was incubated
in each well of a Polysorb strip for 2 h. The surface of the
well was then blocked with TBST supplemented with 2%
BSA and 0.1% Tween 20 for 1.5 h. After washing, increasing
concentrations of biotin-HA were incubated for 2 h, washed
six times with TBST (without protein), incubated for 1 h
with streptavidin-alkaline phosphatase, washed six times in
TBST, and finally incubated with p-nitrophenyl phosphate.
The A405 of the strips were determined each hour for 3 h.
Cell Surface Biotinylation and Immunoprecipitation—Four
different 315-HARE clones (17.5, 29, 30, and 36) were grown
to confluence in T-25 tissue culture flasks. After a 60-min incubation in serum-free medium, the cells were washed twice
with cold PBS and incubated in the presence or absence of
0.05% digitonin (45) in PBS for 10 min at 4 °C. The cells were
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then washed twice with cold PBS and treated with 2 mm
sulfo-NHS-SS-biotin in PBS for 30 min at 4 °C. The biotinylation reaction was terminated by washing and then incubating the cells with 100 mm glycine, pH 8.0, in PBS for 20 min
at 4 °C to quench unreacted sulfo-NHS-SS-biotin. Washed
cells were then lysed in 0.5% Nonidet P-40 PBS containing
200 μm phenylmethylsulfonyl fluoride, 1.0 μg/ml pepstatin,
and 1.0 μg/ml leupeptin for 1 h at 4 °C, and cell lysates were
cleared by centrifugation at 14,000 × g for 10 min at 4 °C. The
resulting supernatant was used for immunoprecipitation experiments. Anti-rat HARE mAb-159 (2 μg/ml) was added to
1.0 ml of supernatant, which was incubated with rotation for
2 h at 4°C, and immune complexes were then collected with
20 μl of 250 μg/ml Protein A/G-Plus-agarose overnight at 4
°C. The resin was washed three times with cold PBS, and the
pellet was resuspended in 30 μl of 2× Laemmli sample buffer without reducing agent, incubated for 3 min at 90 °C, and
subjected to SDS-PAGE and Western analysis.

Results
Two Isoforms of HARE Are Expressed from a Single 315HARE cDNA—Results from previous studies showed that
HARE is a cell surface receptor that clears HA, CS, and advanced glycation end products from the circulatory and lymphatic systems. Studies of HARE or stabilin/FEEL-2 in other
laboratories focused only on the large isoform, disregarding
the possibility of a smaller isoform (i.e. the 190-kDa HARE).
However, we have shown that the smaller isoform of the recombinant rat (29) or human HARE (37) is a recycling endocytic receptor specific for HA and multiple CS types that operates via the coated pit endocytosis pathway. To study the
specificity and function of the large human HARE, we amplified and cloned the open reading frame from pooled lymph
node cDNA and inserted the full-size 315-HARE cDNA into
the expression vector pcDNA5/FRT/V5-His-TOPO. Except
for the absence of the secretion signal, this is the same vector
that we used previously to express and characterize the independent function of the 190-HARE.
The full-length 315-kDa HARE type I membrane protein
contains an extracellular domain with four cysteine-rich fasciclin/epidermal growth factor-like domains of unknown
function, an extracellular LINK domain, a cytoplasmic domain, and a single membrane domain (Figure 1A). The 190HARE is identical to the C-terminal 1417 amino acids of the
full-length HARE (Figure 1A), which we previously suggested arises by proteolytic cleavage (29, 37).
The six cell lines used in this study each contain a single
315-HARE cDNA integrated at the single correct recombinase-specified site in Flp-In 293 cells, as confirmed by their
resistance to hygromycin B, lack of β-galactosidase activity,
and sensitivity to zeocin. The amount of 315-HARE expression in all six cell lines was only ~12% of that observed for
recombinant 190-HARE expressed alone in the same cells
using the same promoter and growth conditions (37). Nonetheless, all six cell lines mediated specific HA endocytosis
over 4 h that was well above the background level of the parental Flp-In 293 cells or cells transfected with vector alone
(not shown).
Unexpectedly, all cell lines expressing the single cDNA encoding full-length 315-kDa HARE produced two individual
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Figure 1. Schematic of the two HARE isoforms and their expression
in stable cell lines. A, the scheme illustrates the domain organization
of the 315- and 190-kDa HARE proteins. The four Cys-rich domains
are 37–39% identical (~50% similar) to each other. Each receptor isoform contains one LINK domain, one transmembrane region, and one
cytoplasmic domain. The arrow indicates the N terminus of the 190kDa HARE (Ser1136), which may be the site of cleavage to create this
isoform. B, in order to assess the cellular ratios of 315- to 190-HARE
isoforms, cells were scraped from T-25 flasks, washed, and resuspended in PBS with 0.5% Nonidet P-40 and protease inhibitors. The
cell lysates were incubated with rotation at 4 °C for 1 h and centrifuged to remove cell debris, and total protein content of each sample
was quantified using the Bradford assay (46). Lysate protein (20 μg)
was analyzed by SDS-PAGE and Western blots. The 315-HARE (filled
arrow) and 190-HARE (open arrow) were detected by chemiluminescence using polyclonal anti-V5 antibody. C, the blot was stripped and
reprobed with anti-actin antibody to allow samples to be normalized to
cellular protein content.

HARE proteins with molecular masses of ~315 and 190 kDa
as detected in Western blots using an antibody against the
C-terminal V5 epitope (Figure 1B). The native spleen and
recombinant 190-HAREs migrated identically in 5% SDSPAGE with the 190-kDa species in these 315-HARE cell lines
(not shown). The HARE expression patterns among all the
cell lines were virtually identical, and the majority of the
recombinant protein migrated at ~315 kDa with a lesser
amount migrating at 190 kDa (Figure 1B). All cell lines produced approximately the same amount of 315-kDa receptor relative to cellular actin (1.9 ± 0.2 for the six samples in
Figure 1, B and C) and produced similar ratios of the 315kDa to 190-kDa HARE (2.7 ± 0.4 for the experiment in Figure
1B). The 315/190-HARE ratio was typically 3–4:1 in multiple
Western analyses using detection by either chemiluminescence or alkaline phosphatase.
Recombinant HARE Appears to Be Folded and Glycosylated
Correctly and Specifically Binds HA—Although we do not
know why expression of the recombinant full-length HARE
was lower than the independently expressed 190-HARE,
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Figure 2. Both recombinant human 315- and 190-kDa HARE isoforms
cross-react with rat anti-HARE mAbs. Whole cell lysates were subjected to reducing (R) or nonreducing (NR) conditions, separated by
5% SDS-PAGE, and electrotransferred to nitrocellulose as described
under “Experimental Procedures.” Nitrocellulose was cut into strips
and blocked with TBST/BSA, and each strip was incubated with 1 μg/
ml mouse IgG or one of the eight indicated mAbs raised against the rat
175-kDa HARE (28, 33). The 315-kDa HARE (filled arrows) and the
190-kDa HARE (open arrows) proteins were recognized by mAbs 30,
154, and 159 in the nonreduced samples, whereas both receptors reacted with only mAb 159 when reduced. The anti-V5 lane (far right)
was a positive control for mAb detection.

we suspect that overexpression of such a large protein containing 202 cysteines might overwhelm the endoplasmic reticulum systems that facilitate protein folding and disulfide
bond formation. The two expressed receptors appear to be
folded correctly based on their reactivity with three anti-rat
mAbs that cross-react with human HARE (Figure 2) and the
specific HA binding activity of each recombinant protein in
ligand blot and cell culture assays. mAbs 30, 154, and 159 detected both the larger and smaller HARE proteins in whole
cell lysates of 315-HARE-transfected cells (Figure 2, NR). Reduction of the proteins with dithiothreitol resulted in detection by only mAb 159 (Figure 2, R), confirming that mAbs
30 and 154 recognize conformational (e.g. sulfhydryl-dependent) epitopes, perhaps within the Cys-rich epidermal
growth factor-like domains that are conserved between rat
and human HARE proteins. Using SDS-PAGE to resolve
the two HARE species, we verified that both receptors specifically bind 125I-HA in a ligand blot assay (Figure 3A). The
above results demonstrate that the 190-kDa protein produced by 315-HARE cell lines is a HARE isoform and not an
artifact of the assays performed. In addition, stable cell lines
containing the empty vector alone do not show mAb- or HAbinding bands at these Mr positions (not shown).
Reduction by dithiothreitol, followed by alkylation to
block refolding via disulfide bond formation, dramatically
shifted the migration of the 190-HARE species to apparently
larger mass (Figure 3B). The decreased migration of the reduced 315-HARE through 5% SDS-PAGE was less apparent,
since migratory shifts in a protein of this size are more difficult to demonstrate. Also, the rod-like geometry of the nonreduced and reduced full-length receptor may contribute
to their similar migration patterns (51). We conclude from
Western blot and silver stain (not shown) analyses of reduced
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Figure 3. The nonreduced 315- and 190-kDa HARE proteins specifically bind HA. Whole cell lysates from cells stably expressing recombinant 315-kDa HARE were subjected to either reduction and then alkylation or nonreducing conditions, followed by 5% SDS-PAGE and
electrotransfer to nitrocellulose membranes. A, a ligand blot (LB) assay was first performed by incubating the nitrocellulose with 1 μg/ml
125I-HA either alone or mixed with a 100-fold excess of unlabeled HA,
washing, and autoradiography as described under “Experimental Procedures.” B, following the ligand blot, the nitrocellulose membrane was
rehydrated in TBST/BSA, and Western blot (WB) analysis was performed using anti-V5 antibody to identify hHARE. C, the 315-HARE
protein was immunoprecipitated from cell lysates with mAb 30, eluted
from the resin with 0.1% SDS, and digested overnight with endoglycosidase F. After electrophoresis and electrotransfer to nitrocellulose, the
blot was subjected to the 125I-HA ligand blot assay followed by Western blot analysis with anti-V5 antibody.

and nonreduced samples that the recombinant human 315HARE is a single polypeptide and not composed of multiple
subunits linked together by disulfide bonds.
When the full-length hHARE was treated with endoglycosidase F to remove N-linked oligosaccharides, a more pronounced migratory shift was observed (Figure 3C), which was
similar to that observed previously for the recombinant 190HARE and the native rat and human receptor isoforms. Endoglycosidase F treatment did not affect 125I-HA binding, revealing that N-linked glycans are not required for HA binding.
Due to the low amount of recombinant 190-kDa HARE
in the 315-HARE stable cell lines, we were not able to obtain enough purified 190-HARE for N-terminal amino acid
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sequencing. However, we purified the 190-HARE from
a human spleen sample and obtained the sequence NH2LLPNLLMRL. Except for the first amino acid, this sequence
is identical to the presumed sequence for the 190-HARE starting at Ser1136 of the full-length protein. The first Leu in our
sample may be a sequencing error or a real mutation (polymorphism) in the genome of the individual spleen donor.
Cells Expressing HARE Endocytose and Degrade 125I-HA—
Recombinant HARE encoded by the full-length cDNA is biologically active, since cells expressing the protein can endocytose HA. Four different cell lines (17.5, 29, 30, and 36) were
allowed to endocytose 125I-HA with and without competing
nonlabeled HA over a 26-h period (Figure 4A). Unlike the
parent Flp-In 293 cells or cells transfected with vector alone,
315-HARE cells specifically internalized HA. HA uptake increased and reached a steady state accumulation after about
24 h. In addition to internalization, the Flp-In 293 cells were
able to deliver HA to lysosomes, where it was degraded (Figure 4B), presumably by the combined actions of endogenous
lysosomal hyaluronidases, β-N-acetylglucosaminidase, and
β-glucuronidase. Unlike the previously described 190-HARE
cell lines, the 315-HARE clones varied more in their HA endocytic rates and degradation.
We and others showed previously that internalization of
HARE in primary cell cultures or stable cell lines occurs via
a clathrin-coated pit pathway (21, 29, 35, 39). To confirm that
the recombinant 315-kDa HARE mediates endocytosis via
coated pits, we incubated 315-HARE clone 30 cells with 125IHA for 4 h in medium containing increasing amounts of sucrose (Figure 4C). Under hyperosmotic conditions (e.g. ≥0.4
m sucrose), receptor-mediated endocytosis decreased by
>90%, indicating that HA uptake depends on clathrin assembly into coated pits (52–54).
The s315- and s190-HARE Ectodomains Bind 125I-HA—The
secreted s315-HARE ectodomain was purified from cell culture medium via either the His6 tail using nickel-chelate affinity chromatography or anti-V5 immunopurification. Partially
purified s315-HARE appeared to be folded correctly, since it
bound HA in the ligand blot assay (Figure 5A), whereas reduction nullified HA binding, and deglycosylation did not affect HA binding, which were the same results seen with the
membrane-bound 315-HARE. Expression and glycosylation
of the s190 and s315-HARE ectodomains in cell culture were
virtually identical. In addition, the recognition of the soluble
receptors by mAbs 30 and 154 was the same as the membrane
receptors in Western blot or immunoprecipitation assays (not
shown). Both HARE ectodomains also bound comparable
amounts of 125I-HA in the ligand blot assay (Figure 5B).
Since the s315-HARE has HA binding capability comparable with the wild type receptor, we used an ELISA-like assay to estimate the HA binding affinity. Purified s315-HARE
or s190-HARE was plated on Polysorb strips, nonspecific
binding sites were blocked with BSA, and the strips were incubated with increasing amounts of biotin-HA. Bound biotin-HA was detected with streptavidin-alkaline phosphatase.
The binding of biotin-HA to either HARE ectodomain was
almost identical (when normalized to pmol of protein). The
data were fit as second order binding curves (Figure 6) with
a calculated Kd value of 9.9 ± 1.2 nm (p < 0.0001) for the s315HARE and 20.7 ± 6.4 nm (p = 0.0004) for the s190-HARE.
These Kd values are very close to the dissociation constant
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Figure 5. The secreted 315-kDa HARE ectodomain is glycosylated
and functional. A, the s315-HARE was purified by Ni2+ affinity chromatography and reduced with dithiothreitol or deglycosylated with endoglycosidase F treatment as described under “Experimental Procedures.” The deglycosylated receptor retains HA binding activity as
seen in the ligand blot (LB) assay, in contrast to the reduced receptor, which does not bind 125I-HA. Following the ligand blot, the same
membrane was subjected to Western blot (WB) analysis using anti-V5
antibody. B, the s190-HARE and s315-HARE demonstrate comparable 125I-HA-binding activities in the ligand blot assay. A ligand blot assay was performed with increasing amounts of purified s190-HARE or
s315-HARE protein after SDS-PAGE and electrotransfer.
Figure 4. Endocytosis and degradation of 125I-HA by cells expressing
HARE. Four 315-HARE cell lines (clone 30 (▼), clone 29 (●), clone 36
(■), and clone 17.5 (♦) were plated in 24-well plates and grown to confluence. A, after a 60-min incubation in serum-free medium, the cells were
washed with 1 ml of HBSS and allowed to endocytose 1.5 μg/ml 125I-HA
in DMEM supplemented with 0.05% BSA, with or without 150 μg/ml unlabeled HA. At the noted times, medium was aspirated, and the well was
washed three times with 1 ml of HBSS. The cells were lysed in 0.5 ml of
0.3 n NaOH, and radioactivity and protein were determined. The values
shown are the average of duplicates (typically within 10%) for specific
cell-associated cpm/μg of protein: total uptake (no excess HA) minus
the nonspecific uptake (with excess unlabeled HA). Specific uptake and
degradation values, which varied depending on the cell line and time
point, were 77–87 and 62–87%, respectively. B, cell-associated degradation of 125I-HA was determined at the noted times by a cetylpyridinium
chloride precipitation assay, as described under “Experimental Procedures,” using a portion of the neutralized cell lysate from the samples in
A. Degradation values are the average of duplicates. C, 315-HARE cells
mediate HA internalization by a clathrin-coated pit pathway. 315-HARE
clone 30 cells were incubated in medium with 1 μg/ml 125I-HA with (to
assess nonspecific uptake) or without (to assess total uptake) a 100-fold
excess of unlabeled HA and increasing concentrations of sucrose, as indicated. A stock 1.2 m sucrose solution was made in DMEM-BSA and
diluted in DMEM-BSA to give the final concentrations indicated. Prior to
the experiment, cells were incubated at 37 °C in DMEM-BSA for 1 h and
then DMEM-BSA/sucrose for an additional 15 min. At time 0, the 125IHA mixes in DMEM-BSA/sucrose were added, and after 4 h the cells
were washed, and protein content, radioactivity, and specific HA uptake
were determined as described under “Experimental Procedures.” Specific 125I-HA endocytosis without sucrose was 70%. Specific cpm/μg of
protein values for endocytosis are means ± S.D. (n = 3).

value of 7 nm determined for HA-receptor complexes in cells
expressing recombinant 190-HARE (37).
HARE Binds to a Subset of GAGs in Addition to HA—We
previously reported that other GAGs compete with HA for
binding to the 190-HARE. Since it is not known how HARE
binds to its multiple ligands or what domains within the
protein interact with each ligand, the GAG-binding properties of the larger 315-kDa HARE may be different from those
of the smaller HARE. We therefore tested the GAG-binding and internalization properties of cells expressing the
315-HARE to discern whether they were different for this
larger HA-binding receptor. This was tested in endocytosis
assays in which 190-HARE (clone 14) and 315-HARE (clone
30) stable cell lines were allowed to endocytose 125I-HA in
the presence of an excess of different competing GAGs (Figure 7A). These results showed that the GAG-binding profiles
are very similar between cells independently expressing the
190-HARE and cells expressing the 315-HARE (and smaller
amounts of 190-HARE). The ability of all of the CS types to
compete for HA uptake indicates that these GAGs bind at or
near the HA binding site(s) in either HARE ectodomain.
Thus far, all of our binding experiments have used 125IHA and competing nonlabeled GAGs in live cell assays to
obtain evidence that the other GAGs bind to HARE. Since
negative results in these indirect assays do not rule out the
presence of independent binding sites for the other GAGs,
we developed direct binding assays to determine whether
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Figure 6. The s315- and s190-HARE ectodomains bind HA with high
affinity. The s315-HARE and s190-HARE ectodomains were purified by affinity chromatography and electroelution, plated on Polysorb strips in duplicate (0.5 μg/well), and allowed to bind increasing
amounts of biotin-HA as described under “Experimental Procedures.”
After washing, bound biotin-HA was detected with streptavidin-alkaline
phosphatase using p-nitrophenyl phosphate as substrate, and A405
values were normalized per pmol of protein plated. The lines are regression analyses for s315-HARE (solid line, open circles) and s190HARE (dotted line, closed circles) data calculated using the ligand
binding curve-fitting and analysis of variance functions of SigmaPlot
version 10.0. The Kd values for biotin-HA binding to s190- and s315HARE under these experimental conditions were 20.7 ± 6.4 (S.E.) nm
(p = 0.0004) and 9.9 ± 1.2 (S.E.) nm (p < 0.0001), respectively.

other GAGs can bind HARE. To test this possibility, we prepared a panel of eight biotin-GAGs (i.e. chondroitin, CS-A,
CS-B, CS-C, CS-D, CS-E, HA, and HS) and assessed the GAG
binding to HARE using a ligand blot procedure similar to
that described above for 125I-HA (Figure 7B). In this experiment, the s315-HARE was purified by Ni2+-chelate chromatography followed by 5% SDS-PAGE, blotted to nitrocellulose, and incubated with biotin-GAG with or without an
excess of the same nonbiotinylated GAG to determine nonspecific binding. Binding of the biotin-GAG was then detected using 125I-streptavidin and autoradiography. The results showed specific binding of the s315-HARE with CS-C,
CS-D, CS-E, and HA, suggesting that HARE is a clearance
receptor for multiple GAGs (Figure 7B). Biotin-HS did not
bind to the s315-HARE. We know from other experiments
(and longer exposure times of this experiment) that CS-B
and chondroitin also bind to HARE but with a lower affinity
that has yet to be measured (not shown).
A Majority of HARE Resides on Intracellular Vesicles—Since
endocytic recycling receptors are found on the cell surface
and in multiple early endosomal compartments along their
intracellular itinerary, we wanted to determine the distribution of HARE between surface and intracellular compartments. The 190-HARE, for example, is distributed roughly
equally, with ~50% on the cell surface (37). This is similar
to the rat small HARE isoform stably expressed in SK-Hep1
cells, which co-localized with early endocytic markers, such
as clathrin, but not later endosomes or lysosomes (29). An initial assessment of receptor localization was performed using
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Figure 7. 315- and 190-HARE cell lines display similar patterns for
glycosaminoglycan competition of HA endocytosis. A, 315-HARE
clone 30 and 190-HARE clone 41 cells were plated in 12-well plates
and grown to confluence. After a 1-h incubation in serum-free medium,
the cells were washed with 2 ml of HBSS and allowed to endocytose
1.5 μg/ml 125I-HA for 4 h at 37 °C in DMEM supplemented with 0.05%
BSA with or without 30 μg/ml of the noted GAG. The medium was aspirated, the well was washed three times with 2 ml of HBSS, and the
cells were lysed in 1 ml of 0.3 n NaOH. Radioactivity and protein per
sample were determined. The data are expressed as a percentage of
the radioactivity in cells with no other GAG addition. The mean ± S.D.
(n = 6) of duplicates from three separate experiments is shown. B, direct binding of a GAG was assessed by a ligand blot assay in which
the indicated biotin-GAG was incubated alone or with a 4-fold excess
of unlabeled GAG. After washing the membrane strips containing the
protein-GAG complex, the biotin-GAG remaining was detected by autoradiography after incubation with 2.5 μg/ml 125I-Streptavidin. CSC, CS-D, CS-E, and HA bound with HARE with the highest affinity,
whereas CS-B and chondroitin (Chon) bound with a low affinity. No
binding was detected with CS-A or HS. The negative control (far right
lane, top) containing the same amount of s315-HARE was not treated
with any biotin-GAG but was treated with 125I-streptavidin.

fluorescence microscopy in which cells were either permeabilized with 0.05% saponin (Figure 8A) or intact (Figure 8B),
and the fixed cells were probed with mAb-30 against the
315- and 190-HARE proteins. The permeabilized cells contained numerous bright intracellular vesicles with a faint
ring of staining representing the cell surface. In contrast,
nonpermeabilized cells showed only distinct perimeter fluorescence, indicating surface expression (Figure 8B). The fluorescence output from a field of permeabilized cells was ~4–5
times greater than a field of nonpermeabilized cells, confirming that most HARE is intracellular.
Next, we used a biotin-labeling technique to determine
the ratio of internal to surface receptor, because differences
in this ratio could explain the clonal differences in endocy-
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Figure 8. Cellular localization of HARE. 315-HARE clone 30 cells
were grown on glass coverslips, fixed, and treated either with (A) or
without (B) saponin as described in Reference 45 and under “Experimental Procedures.” Anti-HARE mAb 30 followed by rhodamine-labeled anti-mouse secondary antibody was used to detect the receptor. Detergent-permeabilized cells were about 4–5 times brighter than
the untreated cells, indicating that most of the receptor resides in intracellular membrane vesicles. Images of the cells were taken in color,
converted to grayscale, and then black-and-white-inverted to visualize more clearly the cellular details seen in the color images. The cells
shown were representative of all of the cells in a typical field at ×600
magnification. Bars, 10 μm.

tosis of HA among cell lines. Cells from four different 315HARE cell lines were incubated with biotinylation reagent
on ice to prevent constitutive endocytosis and without (nonpermeabilized) or with (permeabilized) 0.05% digitonin to
allow perfusion of the biotinylation reagent to the cell interior. Total HARE was then immunoprecipitated from cell lysates, and Western analysis was performed to compare the
amount of biotinylated HARE (using streptavidin-horseradish peroxidase) and total HARE (using anti-V5 antibody).
The results demonstrated that a majority of the 190-HARE
and 315-HARE in all four clones resides on the interior of the
cell. Cells not treated with digitonin had only their cell surface receptors biotinylated, and the ratio of those receptors
compared with the total receptor content (i.e. anti-V5 staining) was low (Figure 9, A–D, light and dark gray bars). In contrast, most of the HARE in permeabilized cells was biotinylated, and the ratio of biotin-HARE to V5 staining was quite
high, indicating a much greater receptor content inside cells
relative to the surface (Figure 9, A–D, open and solid bars).
Based on these biotin-labeling and the preceding fluorescence experiments, we estimate that only about 5–10% of the
total cellular HARE, for either isoform, is at the cell surface.

Discussion
HARE, which has also been named stabilin-2, Feel-2, and
Fex-2 by other laboratories, is the primary receptor for the
clearance of HA and probably CS from the circulatory and
lymphatic systems. HARE binds not only HA but also other
GAGs, particularly the CS types, with high specificity. HA,
free CS chains, and probably CS proteoglycan fragments,
all of which continuously flow from tissue ECMs, first enter the lymphatic system and encounter the endocytic, recycling HARE in the lymph nodes, where most of these ECM
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Figure 9. Biotinylation analysis of the cellular distribution of the two
HARE isoforms in 315-HARE cell lines. 315-HARE cell lines 17.5
(A), 29 (B), 30 (C), and 36 (D) were plated in tissue culture flasks and
grown to confluence. Cell surface or total cellular receptors were biotinylated using 2 mm sulfo-NHS-SS-biotin for 10 min at 4 °C, respectively, in the absence (not permeabilized) or presence (permeabilized)
of 0.05% digitonin (45). Cells were solubilized with 0.5% Nonidet P-40
plus protease inhibitors and then processed for immunoprecipitation
with mAb 159 and analysis by SDS-PAGE as described under “Experimental Procedures.” After electrophoresis, the proteins were electrotransferred to nitrocellulose and probed with streptavidin-horseradish
peroxidase conjugate, and the same blots were then stripped and reprobed with anti-V5 antibody. The blots were scanned, and the digital
data were expressed as the average (n = 4) ratio of streptavidin/V5 detection (band densities). Shown are 190-kDa HARE (unpermeabilized
(light gray bar) and permeabilized (white bar)) and 315-kDa HARE (unpermeabilized (dark gray bar) and permeabilized (black bar)).

components are degraded. This normal GAG turnover process might be accelerated in wound healing, injury, growth,
and other disease states, including some cancers. Most of the
high molecular mass (>106-Da) HA and, presumably, the
other CS-type GAGs are cleared in the lymph nodes, and the
remaining GAGs that enter the blood stream are cleared by
liver sinusoidal endothelium-associated HARE. The activity
of this GAG clearance system was first observed in experiments using animal models to study HA catabolism (17, 18,
34, 55). In addition to its scavenger activity, HARE located in
the spleen, which is not a clearance organ, may play an important yet unknown role in immune system function.
In this report, we note that human HARE is expressed as
two isoforms that are encoded from the same cDNA (i.e. an
mRNA not subject to alternate splicing). The 190- and 315kDa isoforms are recognized by the same subset of anti-rat
HARE mAbs, and both soluble ectodomains bind HA to the
same extent and with almost the same affinity. Both HARE
isoforms also recognize multiple CS types as well as HA.
We know that cells expressing only the 190-kDa isoform can
function in the absence of the 315-kDa isoform to bind and
internalize HA and other GAGs (37). When both the 315- and
190-kDa HARE are present in the same cells within a tissue,
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we do not yet know whether they can function as independent receptors, as heterooligomeric complexes, or as both.
Based on our experiments with the recombinant HARE
isoforms expressed in stable cell cultures, either together or
the 190-HARE alone, it seems that the biological activities of
these two receptors are remarkably similar. Both HARE isoforms contain the same LINK domain and the two C-terminal Cys-rich domains (Figure 1A). The larger isoform has the
additional two N-terminal Cys-rich domains. These four domains are highly conserved, especially their Cys alignments,
which indicates that their disulfide bond pattern and overall folding are essentially identical. Although the function of
these Cys-rich domains is not known, it is tempting to speculate that they are involved in GAG binding, perhaps with
multiple similar binding sites in each domain. Studies are
in progress to test this possibility. Both HARE isoforms also
contain the same cytoplasmic domain for potential intracellular signaling (e.g. endocytic trafficking).
Thus far, it has not been possible to study the activity of
the membrane-bound 315-HARE independently of the 190kDa receptor, since proteolytic cleavage appears to be the
normal processing pathway for the full-length protein in 293
and other cells (e.g. CHO), as it appears to be in vivo. Despite
the consequent complication of not being able to characterize
the GAG binding and endocytic ability of the 315-kDa HARE
by itself in live cells, we were able to demonstrate that the
soluble ectodomain of the 315-HARE binds directly to CS-C,
CS-D, and CS-E in addition to HA. We also detected a lower
level of s315-HARE binding to CS-B and chondroitin, but the
sensitivity of the ligand blot assay may not be sufficient to
quantify these interactions. We are currently developing alternative assays to address this issue.
The only inconsistency we have observed in the GAGbinding activity of HARE occurred with CS-A. In live cell assays, CS-A competes very effectively with labeled HA (20,
23, 29, 36, 37); however, we could not detect a CS-A-HARE
interaction by ligand blot assays, and we obtained similar
sporadic binding results in ELISA-like assays (not shown).
The binding activity of CS-A may be sensitive to the conditions of our in vitro assays, or the affinity may be too low to
retain a good signal with the washing protocol in these assays. We are currently working to optimize the level of detection with these assays as well as testing whether the 190HARE and 315-HARE have different GAG binding profiles
due to the additional protein domains of the larger isoform.
Expression of the full-length 315-HARE cDNA produces
two protein products of different size but similar function.
The processing of the 315-HARE appears to be a tightly regulated process, since the ratio of 315- to 190-HARE was consistently ~3–4:1 in multiple experiments with the six cell
lines used here. Earlier results also demonstrated a consistent ratio of the two isoforms in rat liver or human spleen
and the possibility that isoform ratios might differ between
tissues (30, 33). From our protein sequencing data, the 190HARE purified from human spleen begins at Ser1136. This Nterminal region does not contain a consensus sequence or
motif for known proteases, and the biological implications of
such an activity are unknown at this time. A goal for future
studies is to prevent processing of the 315-HARE, by use
of inhibitors or mutagenesis, in order to study the cellular
function of this larger isoform in the absence of the 190-kDa
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HARE. In ongoing studies, mutagenesis of a possible adjacent furin-like site (KK1131 to AA1131) did not eliminate the
proteolytic processing in 293 cells. Similarly, studies with a
variety of commonly used protease inhibitors (e.g. cathepsin
L, GM6001, EDTA, E-64, aprotinin) failed to identify a potential protease. We are currently investigating how proteolytic cleavage of HARE occurs, what protease is involved, or
whether HARE itself might be autocatalytic.
Observance of the smaller HARE isoform is not unique
to our laboratory. A report on murine stabilin-2 and human
stabilin-1 provided evidence that human stabilin-2/HARE is
processed to generate the smaller isoform, although the authors did not discuss its presence or consider it relevant (39).
The highly similar protein stabilin-1 also has a smaller isoform of about 140 kDa (56; E. N. Harris, unpublished observations). Potentially, the smaller isoforms of both stabilin-1
and HARE may have different ligand-binding profiles or a
different subset of interacting effector molecules than their
full-length counterparts.
Unlike the large native rat liver HARE isoform, which
contains two large disulfide-bonded subunits of 220 and 250
kDa (33), the recombinant 315-kDa human HARE is a single
polypeptide. By Western analysis, the 315-kDa protein band
did not decrease in size after reduction with dithiothreitol,
and multiple bands were not detected. Reduction of immunoaffinity-purified 315-HARE produced a single band detected by silver staining. In previous studies with purified
315-HARE from human spleen, we found that this isoform
contained two large disulfide-bonded subunits. Although
it is possible that Flp-In 293 cells do not have the capability
of sinusoidal endothelial cells to post-translationally modify HARE in the same fashion, in more recent experiments
with fresher spleen tissue, we did not find multiple subunits
in the large HARE isoform. It thus appears likely that variable extraction or storage conditions influence nonspecific
cleavage of the large protein isolated from tissues. Therefore,
we presently believe that each human HARE isoform is composed of only one type of polypeptide subunit. These results
do not exclude the possible presence of nondisulfide-bonded
HARE homo-oligomers or hetero-oligomers, as noted above.
The expression level of the recombinant 190-HARE in earlier studies (37) was 8–10-fold higher than HARE expression
in any of the 315-kDa HARE cell lines. Since the same cytomegalovirus promoter drives expression of either HARE
isoform, we initially thought there might be a difference in
translation efficiency related to the use of two different signal sequences. To test this, we put the 315-HARE-encoding
cDNA, without the native signal sequence, into the pSecTag
vector containing the Ig-κ chain signal sequence. This is the
same signal sequence used to express the 190-HARE cDNA
(37). The change in signal sequences did not make any difference in 315-HARE expression (not shown), indicating that
lower expression is probably a protein folding or trafficking
issue rather than a difference in transcription or translation.
The 315-HARE has 202 Cys residues, compared with 104
for the 190-HARE, and may simply be much more difficult to
fold and align correctly for disulfide bond formation. Thus,
a higher fraction of the 315-HARE protein may be misfolded
and degraded in the endoplasmic reticulum, compared with
the 190-HARE. The lower expression of 315-HARE may also
account for the greater variability in HA endocytic activity
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among the six cell lines expressing the 315-HARE. This variability may seem surprising given the single uniform insertion site of the HARE cDNA in Flp-In 293 cells. However,
the background genotype will not be identical for any cloned
cell lines, due to random mutations in other genes. Endocytosis and degradation rates may be sensitive to changes in
hundreds of different proteins involved in coated pit cycling,
receptor recycling, endosomal, lysosomal, and other intracellular trafficking pathways. Since the signal (i.e. HARE-mediated HA uptake) is lower, such mutations may have more
noticeable inhibitory effects.
The human HARE LINK domain is 50% identical (65%
similar) to the Gallus gallus (chicken) TSG-6 LINK domain
and 26% identical (44% similar) to the human CD44 LINK
domain. The LINK domain in HARE is a primary candidate
for an HA-binding domain, although we do not yet know if
the epidermal growth factor-like Cys-rich domains facilitate
binding to HA or to some of the other CS types. The LINK
domains from HARE, CD44, and TSG-6 contain four highly
conserved cysteines, which may be required for proper folding to facilitate HA binding. Based on structural studies and
computer modeling, most of the LINK amino acids involved
with HA binding are Tyr (57). Since the results in Figures
5B and 6 show that the HA-binding ability of the s190- and
s315-HARE are essentially the same, the common LINK domain could be responsible for HA binding. Preliminary results show that HA endocytosis by cells stably expressing a
190-HARE LINK-deletion variant is inhibited greatly compared with wild type, but is not eliminated. Currently, we
are investigating whether the HARE LINK domain binds to
HA or CS and if potentially key amino acids identified by
NMR comparison studies of LINK modules are involved.
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